By Judy Newman, Wisconsin State Journal
A Madison company working on three potential ways to stop prostate cancer is moving forward with all three now that investors have put in more money and federal regulators have authorized tests on the third treatment.
Madison Vaccines has drawn another $2 million-plus, bringing total investment in the company, known as MVI, to $11 million.
MVI’s products aim to stop prostate cancer at various stages. The lead drug candidate, MVI-816, already is in the second phase of clinical trials. That means it has made it through safety testing and is now being checked for effectiveness.
MVI-816 is aimed at men who have been treated for prostate cancer and show a high risk that it will spread. The trial is underway at UW-Madison; now, The Johns Hopkins University and the University of California-San Francisco will participate, too. Read more …